| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Drs. Noseworthy, Cross, Auger, Weinshenker, and Rodriguez, and J. Weis, L. Stevens, W. Peterson, and D. Sneve), Biostatistics (Drs. O’Brien and Petterson), and Ophthalmology (Dr. Leavitt), Mayo Clinic and Mayo Foundation, Rochester, MN; and Department of Neurology (Drs. Dodick and Wingerchuk), Mayo Clinic and Mayo Foundation, Scottsdale, AZ.
Address correspondence and reprint requests to Dr. John H. Noseworthy, Department of Neurology, Mayo Clinic/Mayo Foundation, 200 First Street, SW, Rochester, MN 55905; e-mail: noseworthy.john{at}mayo.edu
Objective: To determine whether IV immunoglobulin (IVIg) reverses chronic visual impairment in MS patients with optic neuritis (ON). Methods: In this double-blind, placebo-controlled Phase II trial, 55 patients with persistent acuity loss after ON were randomized to receive either IVIg 0.4 g/kg daily for 5 days followed by three single infusions monthly for 3 months, or placebo. Results: The trial was terminated by the National Eye Institute because of negative results when 55 of the planned 60 patients had been enrolled. Fifty-two patients completed the scheduled infusions, and 53 patients completed 12 months of follow-up. Analysis of this data indicated that a difference between treatment groups was not observed for the primary outcome measure, improvement in logMAR visual scores at 6 months (p = 0.766). Exploratory secondary analyses suggested that IVIg treatment was associated with improvement in visual function (including logMAR visual scores at 6 months and visual fields at 6 and 12 months) in patients with clinically stable MS during the trial. Conclusions: IVIg administration does not reverse persistent visual loss from ON to a degree that merits general use.
This article has been cited by other articles:
|
|
 |
|
  B. J. OSBORNE and N. J. VOLPE Optic neuritis and risk of MS: Differential diagnosis and management Cleveland Clinic Journal of Medicine, March 1, 2009; 76(3): 181 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Niklas, H Sebraoui, E Hess, A Wagner, and F Then Bergh Outcome measures for trials of remyelinating agents in multiple sclerosis: retrospective longitudinal analysis of visual evoked potential latency Multiple Sclerosis, January 1, 2009; 15(1): 68 - 74. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Stangel Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 115 - 124. [Abstract] [PDF]
|
|
|
|
 |
|
 X. Qi, L. Sun, A. S. Lewin, W. W. Hauswirth, and J. Guy Long-term Suppression of Neurodegeneration in Chronic Experimental Optic Neuritis: Antioxidant Gene Therapy Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5360 - 5370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pohl, E. Waubant, B. Banwell, D. Chabas, T. Chitnis, B. Weinstock-Guttman, S. Tenembaum, and for the International Pediatric MS Study Group Treatment of pediatric multiple sclerosis and variants Neurology, April 17, 2007; 68(16_suppl_2): S54 - S65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Qi, A. S. Lewin, L. Sun, W. W. Hauswirth, and J. Guy Suppression of Mitochondrial Oxidative Stress Provides Long-term Neuroprotection in Experimental Optic Neuritis Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 681 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Balcer Clinical practice. Optic neuritis. N. Engl. J. Med., March 23, 2006; 354(12): 1273 - 1280. [Full Text] [PDF]
|
|
|
|
|
|
H. G. Roed, A. Langkilde, F. Sellebjerg, M. Lauritzen, P. Bang, A. Morup, and J. L. Frederiksen A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis Neurology, March 8, 2005; 64(5): 804 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Soelberg Sorensen, J. Haas, F. Sellebjerg, T. Olsson, M. Ravnborg, and the TARIMS Study Group IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS Neurology, December 14, 2004; 63(11): 2028 - 2033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Filippi, M. A. Rocca, E. Pagani, G. Iannucci, M. P. Sormani, F. Fazekas, S. Ropele, O. R. Hommes, and G. Comi European Study on Intravenous Immunoglobulin in Multiple Sclerosis: Results of Magnetization Transfer Magnetic Resonance Imaging Analysis Arch Neurol, September 1, 2004; 61(9): 1409 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Dalakas Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases JAMA, May 19, 2004; 291(19): 2367 - 2375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Manny, M. Hussein, J. Gwiazda, and W. Marsh-Tootle Repeatability of ETDRS Visual Acuity in Children Invest. Ophthalmol. Vis. Sci., August 1, 2003; 44(8): 3294 - 3300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al. Intravenous immunoglobulin in neurological disease: a specialist review J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 440 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 No Benefit from IVIg in Persistent Visual Loss from Optic Neuritis Journal Watch Neurology, September 7, 2001; 2001(907): 7 - 7. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
